Effective Japanese medicine against Alzheimer’s should be approved this year!

A Japanese medicine from the Japanese pharmaceutical company Eisai Co. in partnership with the American pharmaceutical company Biogen Inc. it has been proven in tests to be effective in combating the effects of Alzheimer’s disease.


One of the good news is that the US government has already approved the medication on American soil and it should start being marketed soon.


Thus, both companies have applied to the Ministry of Health for approval of the Alzheimer’s drug that may become the first available in Japan that treats the cause of the disease and slows down the progression of symptoms.

This is great news and we hope that soon the drug will be able to spread around the world and help those who suffer from the disease.


Check here for more information.

The Japanese drug that helps delay Alzheimer’s

The two companies hope to gain approval by the end of the year, following the US Food and Drug Administration’s decision in early January 2023 to grant fast-track approval.

Eisai said it applied to the European Medicines Agency on January 9 for approval to sell the drug in Europe. The company also submitted the drug data to the China National Medical Products Administration in December 2022.


Using an antibody called lecanemab, the new drug co-developed by Eisai and Biogen is for early-stage treatment of the fatal brain-destroying disease.

The drug removes a type of protein called beta-amyloid, which is believed to cause the disease. The protein builds up inside the brain and destroys nerve cells, the Eisai company said.

The company said clinical trials showed the new drug reduced the progression of symptoms, such as poorer memory and impaired judgment, by 27% compared to a placebo.


According to the results of the clinical trial, 12 to 17 percent of those who received the drug experienced side effects such as brain edema and bleeding compared to a group who took a placebo, but most of those who did experience the side effects only suffered mild to moderate symptoms temporarily, Eisai said.

Read too:

The drug is expected to be expensive after Eisai set its US price at $26,500 a year.

The Alzheimer’s Association, a non-profit organization based in the United States, said that 55 million people worldwide are living with Alzheimer’s and other forms of dementia.

A research team from the Japanese Ministry of Health, Labor and Welfare estimated that 6.75 million people will suffer from dementia in Japan in 2025. In 2014, the total costs for patients with dementia in the country, including medical and nursing, were 14.5 trillion yen (approximately R$ 570 billion).

In December 2021, a Japanese health ministry panel declined to approve another Alzheimer’s drug jointly developed by Eisai and Biogen.

We hope that this time the success of the medicine will be proven and that it can help many people around the planet.

Source: Mainichi.JP

Views: 508

receive FREE news from japan

Leave a Comment

Your email address will not be published. Required fields are marked *